Drug Trial Radar · NCT03277690
A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.
Last checked: Nov 20, 2026Latest source record: Nov 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
84
Actual
Start
Sep 26, 2017
Primary completion
Jun 30, 2020
Study completion Aug 31, 2020
Sponsor
- Lead sponsor
- Cortendo ABIndustry
- Sponsor type
- Industry
- First posted
- Sep 11, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a double-blind, randomized, placebo-controlled withdrawal and rescue/restoration study in subjects with endogenous Cushing's Syndrome (CS) previously treated with single-arm, open-label levoketoconazole that will assess efficacy, safety, tolerability, and pharmacokinetics of levoketoconazole.
Conditions
- Endogenous Cushing's Syndrome
Interventions
LevoketoconazoleDrug
During the double-blind Withdrawal Phase, patients will receive up to 1200 mg levoketoconazole daily. During the double-blind Restoration Phase, patients will receive levoketoconazole plus placebo.
PlaceboDrug
During the double-blind Withdrawal Phase, patients will receive placebo tablets. During the double-blind Restoration Phase, patients will receive placebo plus levoketoconazole.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects With Loss of Therapeutic Response to Levoketoconazole Upon Withdrawing to Placebo Compared With the Proportion of Subjects With Loss of Therapeutic Response Upon Continuing Treatment With Levoketoconazole.Time frame: max. 9.5 weeks
Locations
45 sites in 12 countries. Site status is shown where the registry gives one.
Keck Medical Center University of Southern California HCII, Internal Medicine - Keck Hospital
Los Angeles, California
Cedars-Sinai Medical Center, Cedars-Sinai Pituitary Center
Los Angeles, California
UCLA School of Medicine, Medicine/Endocrinology Department
Los Angeles, California
The Center for Diabetes and Endocrine Care
Fort Lauderdale, Florida
Emory University, Neurosurgery
Atlanta, Georgia
Northwestern University, Medicine - Endocrinology
Chicago, Illinois
Johns Hopkins University, Endocrinology Department
Baltimore, Maryland
University of Michigan, Comprehensive Endocrine Research, Internal Medicine - MEND
Ann Arbor, Michigan
Washington University School of Medicine, Endocrinology
St Louis, Missouri
Columbia University, College of P&S Medicine/Neuro-endocrine Unit
New York, New York
Memorial Sloan Kettering Cancer Center, Endocrinology
New York, New York
Oregon Health & Science University, Neurological Surgery
Portland, Oregon
Allegheny Neuroendocrinology Center, West Penn Allegheny Health System
Pittsburgh, Pennsylvania
Alexandovska University Hospital, Clinic of Endocrinology & Metabolic Diseases
Sofia, Bulgaria
University Multiprofile Hospital for Active Treatment "Aleksandrovska" EAD Clinic of Endocrinology and Metabolic Diseases
Sofia, Bulgaria
University Specialized Hospital for Active Treatment in Endocrinology (USHATE) I Klinika
Sofia, Bulgaria
Rigshospitalet, Copenhagen University Hospital, Endocrinology Department
Copenhagen, Denmark
APHM Hôpital de la Conception, Service d'Endocrinologie, Diabète et Maladies Métaboliques
Marseille, Cedex 5, France
Evangelismos Athens General Hospital, Department of Endocrinology
Athens, Greece
General Hospital of Athens 'G. Gennimatas', Department of Endocrinology-Diabetes Centre
Athens, Greece
General Hospital of Athens 'Laiko', "National and Kapodistrian University of Athens Medical School Pathophysiology - Endocrinology"
Athens, Greece
University General Hospital of Ioannina, Department of Endocrinology
Ioannina, Greece
Hippokration General Hospital, "Endocrinology and Diabetes Department
Thessaloniki, Greece
Semmelweis Egyetem II. Belgyógyászati Klinika A.épület I.emelet ODM-labor
Budapest, Hungary
Bnai Zion Medical Center, Institute of Endocrinology
Haifa, Israel
Rabin Medical Center- Beilinson Hospital, "Institute of Endocrinology & Metabolism, Beilinson Campus"
Petah Tikva, Israel
Tel-Aviv Sourasky Medical Center Institute of Endocrinology, Metabolism and Hypertension
Tel Aviv, Israel
Clinica di Endocrinologia e malattie del Metabolismo, Dipartimento Specialità Mediche
Ancona, Italy
University of Genova, Department of Internal Medicine & Medical Specialties (DiMI)
Genova, Italy
AOU Policlinico G. Martino Sezione di Endocrinologia
Messina, Italy
AOU Federico II, Sezione di Endocrinologia (Edificio 1, Secondo Piano)
Naples, Italy
Policlinico Agostino Gemelli, Università Cattolica del Sacro Cuore, Endocrinology
Roma, Italy
Policlinico Universitario Sant'Andrea, Scienze Mediche
Roma, Italy
AOU Citta della Salure e della Scienza SC Endocrinologia, Diabetologia e Metabolismo
Torino, Italy
Leiden University, Leiden University Medical Center, Department of Endocrinology
Leiden, Netherlands
Erasmus Medical Center, Department of Internal Medicine
Rotterdam, Netherlands
Maria Sklodowska-Curie Memorial Institute - Cancer Center Gliwice Branch, Nuclear Medicine and Endocrine Oncology Department
Gliwice, Poland
Instytut Centrum Zdrowia Matki Polki, Oddział Endokrynologii i Chorób Metabolicznych
Lodz, Poland
Wojskowy Instytut Medyczny, Klinika Gastroenterologii, Endokrynologii I Chorob Wewnetrznych
Warsaw, Poland
Institutul National de Endocrinologie C.I. Parhon, Sectia Clinica de Endocrinologie II, Patologia tiroidei de corelatie
Bucharest, Romania
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.